NEW YORK (GenomeWeb) – MDxHealth said today that American Pathology Partners will promote and co-market the firm's ConfirmMDx for Prostate Cancer test in the US.

American Pathology Partners is building a network of pathology labs in the US and has partnered in that effort with UniPath in Denver, Palm Beach Pathology in West Palm Beach, Fla., and Eastern Carolina Pathology in Wilson, NC. MDxHealth said the agreement extends its customer base to pathologists serving urologists in key geographic markets.

Financial and other terms of the agreement weren't disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.